3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
13
Genitourinary
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
5
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Interventions
pembrolizumab
7
Nivolumab
4
Carboplatin
4
Taxes
3
Paclitaxel
3
Gene Expression Profiling
3
rucaparib
2
aflibercept
2
Radiotherapy
2
Polymerase Chain Reaction
2
Leucovorin
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Fluorouracil
2
Drug Therapy
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
veliparib
1
trastuzumab deruxtecan
1
tocilizumab
1
selinexor
1
olaparib
1
liposomal doxorubicin
1
eribulin
1
entinostat
1
dehydroftorafur
1
cc-486
1
cabozantinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
rucaparib
×
Genitourinary
×
Clear all
NCT04676334
2024-05-07
CATCH-R
pharmaand GmbH
Phase 3
Completed
34 enrolled
9 charts
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts